Among those receiving tirzepatide, 98.5% lost at least 5% of their body weight from baseline to 88 weeks, 94% lost at least 10% of their body weight, 87.1% lost at least 15% of their body weight, 72.6% achieved a 20% or higher weight loss and 56.6% had a weight reduction of at least 25%
Schedule a consultation with our team to start building your personalized plan.
External resources Semaglutide as a GLP-1 Agonist: A Breakthrough in Obesity Treatment (PubMed Central) Spotlight on the Mechanism of Action of Semaglutide (PubMed Central) How Does Ozempic Work
The good, the bad, and the ugly of ROS: New insights on aging and aging-related diseases from eukaryotic and prokaryotic model organisms
The TEM results gave the direct evidence for GSH-induced aggregation
Thus, our growing library of incretin and hormone receptor agonists is thoroughly validated using our proprietary incretin reporter cells, ensuring that each molecule delivers consistent and biologically relevant activity